Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 3/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567448 | 0.83 | HTR1A (0.38) | ACVR2ATGFBR2CYP2C9KCNH2FFAR1 | |
| SCHEMBL24310078 | 0.83 | HTR1A (0.38) | ACVR2ATGFBR2CYP2C9KCNH2FFAR1 | |
| SCHEMBL24310780 | 0.82 | ACVR2A (0.36) | ACVR2ATGFBR2CYP2C9KCNH2IRAK1 | |
| SCHEMBL24309478 | 0.81 | IRAK1 (0.34) | ACVR2ATGFBR2CYP2C9KCNH2FFAR1 | |
| SCHEMBL24309990 | 0.76 | CYP19A1 (0.36) | ACVR2ATGFBR2CYP2C9KCNH2FFAR1 | |
| SCHEMBL24309806 | 0.74 | EGFR (0.31) | — | |
| SCHEMBL24309799 | 0.72 | CYP2C9 (0.32) | ACVR2ATGFBR2CYP2C9KCNH2IRAK1 | |
| SCHEMBL24309764 | 0.72 | USP1 (0.32) | — | |
| SCHEMBL24310671 | 0.70 | JAK2 (0.36) | IRAK1IRAK4 | |
| SCHEMBL26811279 | 0.69 | HTR1A (0.43) | ACVR2ATGFBR2CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |